Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies in subjects with asthma

Table 4 MEDI-528 Multiple-Dose Pharmacokinetic Parameters in Study 1

Cohort	C_max (μg/mL)	T_max (day)	T_1/2 (day)	Accumulation index*
0.3 mg/kg (n = 9)	13.7 ± 2.7^†	3.5 ± 2.1^†	37.1 ± 7.5^†	5.2 ± 2.0^‡
1 mg/kg (n = 9)	52.1 ± 33.0	3.7 ± 2.3	35.0 ± 11.5	9.9 ± 4.5
3 mg/kg (n = 9)	105.5 ± 31.0	3.9 ± 2.6	37.7 ± 7.5	6.7 ± 1.8

Values are mean ± SD. C_max = maximum concentration; T_max = time to maximum concentration; T_1/2 = half-life.
*Accumulation index was based on trough concentration after first and last dose.
^†n = 8.
^‡n = 7.

ISSN: 1471-2466